Related Experiment Video
Updated: Aug 13, 2025
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
D Rhamnose β-hederin Reverses NAP1L5-mediated Adriamycin Resistance in Breast Cancer
Context:
The persistent use of anticancer medicines can cause multidrug resistance in many tumors and serious cytotoxicity for healthy cells, including adriamycin (ADR), a treatment for breast cancer (BC). Cell resistance to ADR in patients with recurrent advanced BC can occur. Creating effective treatments that can grapple with multidrug resistance is still challenging. Traditional Chinese medicine (TCM) may offer a solution in D Rhamnose beta-hederin (DRβ-H), an oleanane type of triterpenoid saponin.
Objective:
The study intended to assess the ability of DRβ-H to inhibit the ADR resistance of two BC-lineage cell lines, MCF-7 and SUM-1315, and to explore the causal link between DRβ-H and the reversal of chemoresistance.
Design:
The research team performed a cell biology study.
Setting:
The study took place at laboratory in China.
Outcome Measures:
The research team: (1) assessed cell viability and the migration and invasion the cell lines; (2) investigated the molecular mechanism and identified the downstream targets of DRβ-H, and (3) comprehensively examined the expression pattern, underlying functions, and evident prognostic significance of NAP1L5 in BC by gathering the online information available.
Results:
DRβ-H can inhibit the viability of the MCF-7/ADR and SUM-1315/ADR cancer cells in a dosage-dependent manner. NAP1L5 might be the main target of DRβ-H in reversing ADR resistance. Its expression decreased in BC cells, and the more advanced the BC was, the lower the NAP1L5 expression was.
Conclusion:
DRβ-H at nontoxic concentrations was related to ADR resistance in BC through its downstream target NAP1L5. NAP1L5 is potentially a preferable prognostic marker for BC.
Insights
D Rhamnose beta-hederin (DRβ-H) inhibits adriamycin (ADR) resistance in breast cancer (BC) cells by targeting NAP1L5. This discovery offers a new approach to overcoming multidrug resistance in BC treatment.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Anticancer drug resistance, including adriamycin (ADR) resistance in breast cancer (BC), poses a significant clinical challenge.
- Multidrug resistance (MDR) in advanced and recurrent BC necessitates novel therapeutic strategies.
- Traditional Chinese Medicine (TCM) offers potential solutions, such as D Rhamnose beta-hederin (DRβ-H), a triterpenoid saponin.
Purpose of the Study:
- To evaluate the efficacy of DRβ-H in overcoming ADR resistance in BC cell lines.
- To elucidate the molecular mechanisms underlying DRβ-H's action in reversing chemoresistance.
- To investigate the role of NAP1L5 as a potential target and prognostic marker in BC.
Main Methods:
- Cell biology techniques were employed to assess cell viability, migration, and invasion.
- Molecular mechanisms and downstream targets of DRβ-H were investigated.
- Expression patterns and prognostic significance of NAP1L5 in BC were analyzed using available online data.
Main Results:
- DRβ-H demonstrated a dose-dependent inhibition of viability in ADR-resistant MCF-7/ADR and SUM-1315/ADR cells.
- NAP1L5 was identified as a potential key target of DRβ-H in reversing ADR resistance.
- NAP1L5 expression was found to be inversely correlated with BC progression and stage.
Conclusions:
- DRβ-H can overcome ADR resistance in BC at non-toxic concentrations by modulating its downstream target, NAP1L5.
- NAP1L5 shows potential as a prognostic biomarker for breast cancer patients.
More Related Videos
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
07:56Bacterial Delivery of RNAi Effectors: Transkingdom RNAi
Published on: August 18, 2010
